[{"id":12130,"link":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/advanced-biodesign\/","name":"advanced-biodesign","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/wp-content\/uploads\/sites\/1470\/2024\/11\/ADVANCED-BIODESIGN-1.png","alt":""},"title":"ADVANCED BIODESIGN","author":{"name":"cmarchandin","link":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/author\/cmarchandin\/"},"date":"Nov 18, 2024","dateGMT":"2024-11-18 20:01:31","modifiedDate":"2024-12-05 16:44:16","modifiedDateGMT":"2024-12-05 15:44:16","commentCount":"0","commentStatus":"closed","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":5,"sec":1},"status":"publish","excerpt":"Founded by Ismail Ceylan in 2010, ABD is a groundbreaking biotech company with a strong leadership team"},{"id":11903,"link":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/apmonia-therapeutics\/","name":"apmonia-therapeutics","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/wp-content\/uploads\/sites\/1470\/2024\/11\/Logos-site-GALIEN-HLTH-2024-11.png","alt":""},"title":"Apmonia Therapeutics","author":{"name":"admin","link":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/author\/admin\/"},"date":"Nov 14, 2024","dateGMT":"2024-11-14 21:17:58","modifiedDate":"2024-11-26 20:03:49","modifiedDateGMT":"2024-11-26 19:03:49","commentCount":"0","commentStatus":"closed","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":52},"status":"publish","excerpt":"Apmonia Therapeutics is a biotechnology company dedicated to developing therapeutic strategies towards cancer. They are developing a first-in-class pipeline of next-generation peptide-based therapies targeting the tumor microenvironment to improve the lives of patients with cancer."},{"id":11920,"link":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/aviwell\/","name":"aviwell","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/wp-content\/uploads\/sites\/1470\/2024\/11\/Aviwell-1.png","alt":""},"title":"Aviwell","author":{"name":"admin","link":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/author\/admin\/"},"date":"Nov 14, 2024","dateGMT":"2024-11-14 21:46:56","modifiedDate":"2024-11-26 20:12:20","modifiedDateGMT":"2024-11-26 19:12:20","commentCount":"0","commentStatus":"closed","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":42},"status":"publish","excerpt":"Aviwell is pioneering a revolutionary approach to feed additives that offers direct benefits to livestock producers. Aviwell addresses the inefficiencies in livestock production by harnessing the natural diversity of the gut microbiome. This cutting-edge approach aligns with consumer demand for organic, sustainable products. Built on its proprietary AI\/ML platform, Aneto\u2122, Aviwell\u2019s natural, sustainable feed solutions are designed to significantly improve animal health and production efficiency, delivering measurable gains to producer operations."},{"id":11899,"link":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/biper-therapeutics\/","name":"biper-therapeutics","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/wp-content\/uploads\/sites\/1470\/2024\/11\/Original.png","alt":""},"title":"BiPER Therapeutics","author":{"name":"admin","link":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/author\/admin\/"},"date":"Nov 14, 2024","dateGMT":"2024-11-14 21:07:25","modifiedDate":"2024-11-25 15:45:02","modifiedDateGMT":"2024-11-25 14:45:02","commentCount":"0","commentStatus":"closed","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":9},"status":"publish","excerpt":"BiPER Therapeutics develop first-in-class therapeutics pushing tumors to burn out, a unique approach and a new way to treat cancers. Their first clinical candidate, BPR001-615 is at 9 months from the clinic to treat gastro-intestinal cancers"},{"id":12159,"link":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/brenus-pharma\/","name":"brenus-pharma","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/wp-content\/uploads\/sites\/1470\/2024\/11\/Brenus-1.png","alt":""},"title":"Brenus Pharma","author":{"name":"cmarchandin","link":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/author\/cmarchandin\/"},"date":"Nov 18, 2024","dateGMT":"2024-11-18 18:18:52","modifiedDate":"2024-12-18 17:49:50","modifiedDateGMT":"2024-12-18 16:49:50","commentCount":"0","commentStatus":"closed","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":3},"status":"publish","excerpt":"Brenus Pharma is a French pioneering biotech with the mission to prevent cancer recurrence, the main challenge in solid tumors that causes 10M fatalities each year worldwide."},{"id":11982,"link":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/cilcare\/","name":"cilcare","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/wp-content\/uploads\/sites\/1470\/2024\/11\/Logos-site-JPM-2025-2.png","alt":""},"title":"Cilcare","author":{"name":"admin","link":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/author\/admin\/"},"date":"Nov 15, 2024","dateGMT":"2024-11-15 19:21:00","modifiedDate":"2024-11-27 16:26:20","modifiedDateGMT":"2024-11-27 15:26:20","commentCount":"0","commentStatus":"closed","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":44},"status":"publish","excerpt":"Cilcare is a biotech dedicated to harnessing auditory sciences to reshape the future of care via early diagnosis and targeted treatment."},{"id":12648,"link":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/dolinnov\/","name":"dolinnov","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/wp-content\/uploads\/sites\/1470\/2024\/12\/Dolinnov.png","alt":""},"title":"Dolinnov","author":{"name":"lzaim","link":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/author\/lzaim\/"},"date":"D\u00e9c 3, 2024","dateGMT":"2024-12-03 20:09:25","modifiedDate":"2024-12-03 23:02:00","modifiedDateGMT":"2024-12-03 22:02:00","commentCount":"0","commentStatus":"closed","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/pharma\/\" rel=\"category tag\">Pharma<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a> <a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/pharma\/\" rel=\"category tag\">Pharma<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":40},"status":"publish","excerpt":"Dolinnov aims to develop an innovative therapeutic approach based on antisense technology to treat chronic pain, particularly neuropathic and inflammatory pain. The company specifically targets a novel therapeutic target within the peripheral nervous system, concentrating on the dorsal root ganglia (DRG)."},{"id":12007,"link":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/h-a-c-pharma\/","name":"h-a-c-pharma","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/wp-content\/uploads\/sites\/1470\/2024\/11\/HAC-Pharma-2.png","alt":""},"title":"H.A.C. Pharma","author":{"name":"admin","link":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/author\/admin\/"},"date":"Nov 15, 2024","dateGMT":"2024-11-15 19:52:35","modifiedDate":"2024-12-09 18:10:19","modifiedDateGMT":"2024-12-09 17:10:19","commentCount":"0","commentStatus":"closed","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/pharma\/\" rel=\"category tag\">Pharma<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a> <a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/pharma\/\" rel=\"category tag\">Pharma<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":5},"status":"publish","excerpt":"European specialty pharma delivering high therapeutic value medicines to patients. Since 2007, H.A.C. Pharma is delivering mature and innovative high value drugs to patients through distribution, in-licensing and acquisition deals"},{"id":12428,"link":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/inflectis-bioscience\/","name":"inflectis-bioscience","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/wp-content\/uploads\/sites\/1470\/2024\/11\/Logos-site-JPM-2025-18.png","alt":""},"title":"InFlectis BioScience","author":{"name":"cmarchandin","link":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/author\/cmarchandin\/"},"date":"Nov 21, 2024","dateGMT":"2024-11-21 19:07:48","modifiedDate":"2024-12-04 23:31:30","modifiedDateGMT":"2024-12-04 22:31:30","commentCount":"0","commentStatus":"closed","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":0,"sec":59},"status":"publish","excerpt":"InFlectis Bioscience is developing first-in-class therapies for neuromuscular diseases and is currently evaluating in clinic an orally available small molecule, named IFB-088 (icerguastat) that has the potential to extend lives or improve the quality-of-life for people suffering from Amyotrophic Lateral Sclerosis (ongoing phase II clinical trial) and demyelinating diseases like Charcot-Marie-Tooth disease (phase 2 ready package)."},{"id":11907,"link":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/lys-therapeutics\/","name":"lys-therapeutics","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/wp-content\/uploads\/sites\/1470\/2024\/11\/Lys-Therapeutics.png","alt":""},"title":"Lys Therapeutics","author":{"name":"admin","link":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/author\/admin\/"},"date":"Nov 14, 2024","dateGMT":"2024-11-14 21:23:46","modifiedDate":"2024-12-09 15:22:19","modifiedDateGMT":"2024-12-09 14:22:19","commentCount":"0","commentStatus":"closed","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":2},"status":"publish","excerpt":"Lys Therapeutics is a pioneering biotechnology company revolutionizing the treatment of patients with neurodegenerative or neurovascular diseases by targeting blood-brain barrier (BBB) dysfunctions."},{"id":11932,"link":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/okomera\/","name":"okomera","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/wp-content\/uploads\/sites\/1470\/2024\/11\/Okomera.png","alt":""},"title":"Okomera","author":{"name":"admin","link":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/author\/admin\/"},"date":"Nov 15, 2024","dateGMT":"2024-11-15 15:12:39","modifiedDate":"2024-12-04 22:57:44","modifiedDateGMT":"2024-12-04 21:57:44","commentCount":"0","commentStatus":"closed","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/medtech\/\" rel=\"category tag\">Medtech<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a> <a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/medtech\/\" rel=\"category tag\">Medtech<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":29},"status":"publish","excerpt":"Based in France and the United States, Okomera is a pioneering biotech startup transforming drug discovery with advanced microfluidic technology and AI. Okomera\u2019s miniaturized, automated platform tests the effects of various therapeutic candidates on tumoroids derived from patient microbiopsies."},{"id":11884,"link":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/oncodesign-precision-medicine\/","name":"oncodesign-precision-medicine","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/wp-content\/uploads\/sites\/1470\/2024\/11\/OPM.png","alt":""},"title":"Oncodesign Precision Medicine","author":{"name":"admin","link":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/author\/admin\/"},"date":"Nov 14, 2024","dateGMT":"2024-11-14 19:39:57","modifiedDate":"2024-12-13 19:59:38","modifiedDateGMT":"2024-12-13 18:59:38","commentCount":"0","commentStatus":"closed","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":0},"status":"publish","excerpt":"Oncodesign Precision Medicine (OPM), founded in 2022, is a biopharmaceutical company specializing in precision medicine, dedicated to the discovery of treatments for resistant and metastatic cancers."},{"id":12432,"link":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/pepkon\/","name":"pepkon","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/wp-content\/uploads\/sites\/1470\/2024\/11\/Logos-site-JPM-2025-19.png","alt":""},"title":"PepKon","author":{"name":"cmarchandin","link":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/author\/cmarchandin\/"},"date":"Nov 21, 2024","dateGMT":"2024-11-21 19:26:16","modifiedDate":"2024-11-26 21:29:10","modifiedDateGMT":"2024-11-26 20:29:10","commentCount":"0","commentStatus":"closed","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":58},"status":"publish","excerpt":"PepKon is a French biotech start-up developing first-in-class therapeutic peptides for refractory or incurable cancers. Leveraging ten years of academic research, its lead candidate is a CD47 agonist derived from thrombospondin-1. It acts through a novel, calcium-dependent and selective mechanism of action that kills cancer cells while sparing healthy ones."},{"id":11936,"link":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/qubit-pharmaceuticals\/","name":"qubit-pharmaceuticals","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/wp-content\/uploads\/sites\/1470\/2024\/11\/Logos-site-BIO-2024-Entreprises-3.png","alt":""},"title":"Qubit Pharmaceuticals","author":{"name":"admin","link":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/author\/admin\/"},"date":"Nov 15, 2024","dateGMT":"2024-11-15 15:45:20","modifiedDate":"2024-11-21 17:26:06","modifiedDateGMT":"2024-11-21 16:26:06","commentCount":"0","commentStatus":"closed","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":54},"status":"publish","excerpt":"Qubit Pharmaceuticals is a pioneering deep-tech company specializing in the discovery and design of novel drug candidates for complex targets, by leveraging cutting-edge molecular simulation technologies, hybrid High-Performance Computing (HPC), and Artificial Intelligence (AI). Qubit Pharmaceuticals stands at the forefront of innovation in pharmaceutical research with their groundbreaking research in quantum computing applied to quantum chemistry that promises to revolutionize drug discovery, offering unprecedented precision and speed into identifying targets, discovering novel molecules and predicting their interactions."},{"id":12146,"link":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/spartacus-biomed\/","name":"spartacus-biomed","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/wp-content\/uploads\/sites\/1470\/2024\/11\/Logos-site-JPM-2025-6.png","alt":""},"title":"Spartacus-Biomed","author":{"name":"cmarchandin","link":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/author\/cmarchandin\/"},"date":"Nov 18, 2024","dateGMT":"2024-11-18 16:50:06","modifiedDate":"2024-11-26 20:35:21","modifiedDateGMT":"2024-11-26 19:35:21","commentCount":"0","commentStatus":"closed","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/medtech\/\" rel=\"category tag\">Medtech<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a> <a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/medtech\/\" rel=\"category tag\">Medtech<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":2,"sec":37},"status":"publish","excerpt":"Spartacus-Biomed is a French ISO13485-compliant innovative company, winner of several grants from the Occitanie region and the French state, focused on developing advanced diagnostic and therapeutic solutions for complex medical conditions."},{"id":11862,"link":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/stromacare\/","name":"stromacare","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/wp-content\/uploads\/sites\/1470\/2024\/11\/Logos-site-GALIEN-HLTH-2024-6.png","alt":""},"title":"StromaCare","author":{"name":"admin","link":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/author\/admin\/"},"date":"Nov 14, 2024","dateGMT":"2024-11-14 19:19:06","modifiedDate":"2024-12-04 23:02:26","modifiedDateGMT":"2024-12-04 22:02:26","commentCount":"0","commentStatus":"closed","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":36},"status":"publish","excerpt":"STROMACARE aims to develop therapeutics that make the stroma 'permeable' to immune cells and other molecules of interest, to eliminate the cancer."},{"id":12187,"link":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/torskal\/","name":"torskal","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/wp-content\/uploads\/sites\/1470\/2024\/11\/Logos-site-JPM-2025-16.png","alt":""},"title":"Torskal","author":{"name":"cmarchandin","link":"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/author\/cmarchandin\/"},"date":"Nov 18, 2024","dateGMT":"2024-11-18 19:44:54","modifiedDate":"2024-11-27 17:28:14","modifiedDateGMT":"2024-11-27 16:28:14","commentCount":"0","commentStatus":"closed","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/medtech\/\" rel=\"category tag\">Medtech<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a> <a href=\"https:\/\/event.businessfrance.fr\/french-corner-at-jp-morgan-week\/category\/medtech\/\" rel=\"category tag\">Medtech<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":24},"status":"publish","excerpt":"TORSKAL is an international biotech\/medtech company and a pioneer in green nanotechnology. The company designs gold nanoparticles for cancer treatment using green chemistry"}]